SQUAWK/NEWS
Account
Theme
Account
Menu
Live News EQUITY ARTICLE M impact

Alzinova starts ALZ-101 Phase II and launches ~$5.5M rights issue

Alzinova began Phase II operational start-up for ALZ-101 in early Alzheimer’s, targeting ~120 patients, with first patient expected around late 2026/early 2027. The company also launched a rights issue of approximately $5.5M to fund initiation and CMC.

ALZ

Alzinova has begun the Phase II operational start-up for ALZ-101 in early Alzheimer’s, with the trial targeting about 120 patients. The company said the first patient is expected around late 2026 or early 2027. Alzinova also launched a rights issue of approximately $5.5M to fund the trial initiation and CMC.

Related stories